PARTNERS:
The Iacocca Family Foundation
The Iacocca Family Foundation entered into an investment partnership with Kineta in June of 2010 to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat type 1 diabetes mellitus. The Foundation has played a leading role in funding important research in both the public and private sectors to further its goal of finding a cure for type 1 diabetes.
MPI Research
MPI Research and Kineta entered into a strategic collaboration in October 2009 to further preclinical work on Kineta's autoimmune program. MPI Research, located in Matawan, Michigan is a global leader among contract research organizations and is focused on preclinical and early clinical research.
COLLABORATORS:
University of Washington
The Kineta vaccine adjuvant development program is a collaborative project with Michael Gale, Jr., Ph.D. and Michael G. Katze, Ph.D. of the University of Washington. The work stems from a $13 million dollar contract award from the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health. Kineta has a $6.8 million subcontract to identify and develop preclinical studies on suitable vaccine adjuvant candidates that target the RIG-I immune pathway. Dr. Gale, an UW Professor of Immunology, Adjunct Associate Professor of Global Health and Microbiology is the Principal Investigator on the contract. Contract number: HHSN272200900035C
Kineta scientists have an ongoing collaboration with George Chandy, M.D., Ph.D. and Jonathan Lakey, Ph.D. of the University of California, Irvine to evaluate ShK-186 in models of type 1 diabetes mellitus and islet cell transplantation. Dr. Chandy continues to be a scientific partner on the advancement of Kineta's autoimmune drug candidate.
National Institutes of Health
The National Institutes of Health has provided funding to Kineta via its Small Business Innovation Research grant program (SBIR) for two areas of work, our discovery stage RIG-I antiviral program and our preclinical, autoimmune program and its applications to multiple sclerosis. Specifically, this support comes from the National Institute of Allergy and Infectious Diseases, award numbers: R43AI081335 and R43 AI85691.
PARTNERING WITH US
Kineta's is currently evaluating high quality, early-stage and pre-clinical compounds to add to our portfolio of drug development programs. We are specifically interested in programs focused on virus infection, inflammation and autoimmune diseases.
Laboratories and companies seeking to out-license programs with demonstrated scientific promise are invited to contact us.
Kineta also seeks development collaborations and future partners on our current programs. For more information on our corporate initiatives, please contact, Bill Cadwallader, Senior Vice President of Corporate Development, bcadwallader@kinetabio.com, 206-378-0400.
